Vanderbilt Ingram Cancer Center
May. 31, 2019—Breast cancer expert Ben Ho Park, M.D., is the new director of Precision Oncology at Vanderbilt-Ingram Cancer Center. Dr. Park explains his groundbreaking research on the genetic events that lead to cancer, and what that means for the future of cancer treatment.
May. 6, 2019—New research by School of Nursing professor Sheila Ridner finds that a special scan measuring lymphatic fluid volume is significantly better than a tape measure at predicting which women undergoing treatment for breast cancer are at risk of developing a common complication resulting from damaged lymph nodes.
Sep. 13, 2018—Researchers led by melanoma researcher Douglas Johnson have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
Jul. 13, 2018—The signs of this rare bile-duct cancer typically go unnoticed at first. Here’s what to know.
Jun. 14, 2018—A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease.
Jun. 12, 2018—After successfully leading Vanderbilt-Ingram Cancer Center (VICC) through years of growth in patient volumes and enhanced care options, Michael Neuss, MD, Chief Medical Officer of the VICC Clinical Enterprise, is retiring as CMO. Neuss will be succeeded by Madan Jagasia, MBBS, MSCI, MMHC, who has been named to the George and Beverley Rawlings Directorship and is section chief, Hematology and Stem Cell Transplant and director of the Outpatient Stem Cell Clinic.
May. 31, 2018—For the 10th year in a row Vanderbilt University Medical Center (VUMC) and Vanderbilt-Ingram Cancer Center (VICC) have been named a CEO Cancer Gold Standard employer by the